Pharming Group Q3 2025 Earnings Report

Pharming Group EPS Results

• Actual EPS: $0.01
• Consensus EPS: $0.00
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: N/A

Pharming Group Revenue Results

• Actual Revenue: $97.30 million
• Expected Revenue: $80.18 million
• Beat/Miss: Beat by +$17.12 million
• YoY Revenue Growth: N/A

Pharming Group Announcement Details

• Quarter: Q3 2025
• Date: 11/6/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Pharming Group (OTCMKTS:PHGUF) N.V. is a Netherlands-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company’s activities include research and development, regulatory approval, manufacturing, and global commercialization of medicines for patients with limited treatment options.

Pharming’s principal product is Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare and potentially life-threatening genetic disorder. Ruconest is produced using Pharming’s proprietary transgenic production technology and is approved in several markets, including the United States and European Union.

The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome, or APDS. Joenja was approved in the United States in 2023 and is intended for patients aged 12 and older with this rare primary immunodeficiency. Pharming continues to evaluate opportunities to expand access to its products and advance additional therapies for rare diseases.

Pharming was founded in 1988 and is headquartered in Leiden, the Netherlands. Its medicines are supplied to patients through commercial and distribution activities in multiple international markets. Sijmen de Vries has served as the company’s chief executive officer and executive director for much of its commercial development.